Halozyme Therapeutics Inc (NASDAQ: HALO) is a biopharma company developing subcutaneous drug delivery platforms and oncology assets. Its ENHANZE® technology allows faster, less invasive drug administration and is licensed to major pharma companies. Halozyme offers investors recurring royalty revenue and a scalable biologics platform.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


